AVXL: Anavex Life Sciences Corp.
About
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Current Value
$8.281 Year Return
Current Value
$8.281 Year Return
Key Details
Market Cap
$698.71M
P/E Ratio
-16.44
1Y Stock Return
22.62%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
5.4
Strategies that include AVXL
Stock's related to AVXL
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -16.30% | $78.15B | +35.51% | 0.42% |
| COR | -14.48% | $47.48B | +21.20% | 0.86% |
| OCX | -13.73% | $42.93M | -36.09% | 0.00% |
| PULM | -10.78% | $19.83M | +202.98% | 0.00% |
| PRPH | -10.74% | $18.14M | -82.61% | 0.00% |
| NEUE | -10.38% | $40.93M | -34.13% | 0.00% |
| TCTM | -10.20% | $8.10M | -42.99% | 0.00% |
| EVH | -9.60% | $1.39B | -58.46% | 0.00% |
| DOGZ | -9.59% | $614.77M | +1,372.26% | 0.00% |
| IMNN | -9.17% | $10.02M | -22.89% | 0.00% |
| ALL | -7.49% | $52.06B | +45.67% | 1.85% |
| CNC | -7.26% | $29.19B | -21.56% | 0.00% |
| ACGL | -6.91% | $36.00B | +16.84% | 0.00% |
| CYD | -6.86% | $364.46M | -2.94% | 4.26% |
| TXO | -6.80% | $737.26M | -1.80% | 13.22% |
| LUMO | -6.75% | $37.45M | +41.97% | 0.00% |
| CI | -6.54% | $89.70B | +12.57% | 1.68% |
| CPB | -5.78% | $12.96B | +7.08% | 3.40% |
| ALAR | -5.75% | $89.09M | +158.08% | 0.00% |
| GEL | -5.51% | $1.44B | +2.81% | 5.24% |
ETF's related to AVXL
News
SeekingAlpha
Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam in the treatement of Alzheimer's.
SeekingAlpha
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the company a Hold rating. Read more here.
SeekingAlpha
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Finnhub
Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation Marwan Noel Sabbagh MD, FAAN,...
Yahoo
Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmac
Yahoo
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the tr
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.